Julia Chapman is Director of Alliance Management for Precision Biosciences, a leader in gene engineering. Julia has a decade of experience in drug development, and she has lived and worked in more than seven countries including the US, UK, Germany, and Italy. She joined Precision from Novartis, where she supported the development of new biologics through approval and launch. Julia also managed Medical Countermeasure and Pandemic Preparedness contracts with the UK and US governments, oversaw supply allocation to more than 40 global markets, and supported the carve-out and reintegration of the Novartis Influenza business to CSL.
Julia completed both her undergraduate and graduate studies at Duke University, with an MBA and a BSE in biomedical engineering.